ELIXCYTE – 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測

Report Overview

KEY INSIGHTS

ELIXCYTE is an allogeneic stem cell product derived from adipose tissue, designed to regulate the immune system, reduce inflammation, and promote chondrocyte proliferation while supporting the normal function of damaged chondrocytes. This therapy for osteoarthritis also helps alleviate pain and maintain the normal structure of cartilage.

By harnessing the regenerative power of stem cells, ELIXCYTE promotes tissue repair and healing, making it a promising candidate in regenerative medicine. Its flexibility in administration, both intravenously and intra-articularly, allows for targeted therapeutic effects, making it suitable for treating a wide range of conditions, including chronic kidney disease, chronic wounds, and retinal degeneration.

This drug is developed by UnicoCell Biomed. UnicoCell Biomed Co Ltd, founded in 2018, is based in Taiwan and focuses on the research and development of stem cell-based drugs, cell therapy technologies, and regenerative medical services. The company offers a variety of services, including the development of new stem cell drugs, sales of stem cell secretions, and cell testing services. UnicoCell Biomed operates throughout Taiwan, providing these specialized services.

MARKET POTENTIAL AND POSITIONING

The market potential for ELIXCYTE is substantial, particularly given the increasing prevalence of osteoarthritis and other age-related conditions worldwide. With its Phase III clinical trial successfully underway and approvals from both the US FDA and Taiwan FDA, ELIXCYTE is well-positioned to become a leading treatment option. Its recognition by the esteemed journal Cytotherapy and the opportunity to present at the ISCT Conference in Vancouver further establish its credibility in the scientific community and highlight its potential impact on the treatment landscape.

As ELIXCYTE continues to prove its efficacy and safety in clinical trials, it is set to capture a significant share of the regenerative therapies market. Its unique role as a non-invasive, stem cell-based solution for irreversible aging-related diseases positions it as a key player in the advancing field of regenerative medicine, with the potential to transform the treatment of chronic and degenerative conditions on a global scale.

REGIONAL ANALYSIS

Inkwood Research offers an analysis of seven key markets:

• United States
• Germany
• France

o In France, the aging population is significantly affected by knee osteoarthritis, a prevalent form of arthritis that causes chronic pain, diminished mobility, and a reduced quality of life for millions of individuals.

o According to industry sources, the number of individuals aged 65 and over in France has grown significantly, reaching around 14.14 million in 2023. This notable increase highlights the broader trend of an aging population in the country.

• United Kingdom
• Italy
• Spain
• Japan

Table of Contents

1. INTRODUCTION TO THE REPORT
2. ELIXCYTE OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.2.3. SAFETY AND EFFICACY
2.3. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. ELIXCYTE MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF ELIXCYTE IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF ELIXCYTE IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF ELIXCYTE IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF ELIXCYTE IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF ELIXCYTE IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF ELIXCYTE IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF ELIXCYTE IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF ELIXCYTE IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF ELIXCYTE IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: ELIXCYTE, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: ELIXCYTE, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: ELIXCYTE MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: ELIXCYTE MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: ELIXCYTE MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: ELIXCYTE MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: ELIXCYTE MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: ELIXCYTE MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: ELIXCYTE MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: ELIXCYTE MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: ELIXCYTE MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: ELIXCYTE MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: ELIXCYTE MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: ELIXCYTE MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: ELIXCYTE MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: ELIXCYTE MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: ELIXCYTE MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: ELIXCYTE MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧